Scarica l'app Stockscreener
4.41
10.00%
-0.49
Mainz Biomed N V Borsa (MYNZ) Ultime notizie
Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com
Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World
MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Mainz Biomed N.V. Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Marketscreener.com
Mainz Biomed Partners with Quest Diagnostics to Advance Colorectal Cancer Screening in the U.S. - Citybuzz
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. - Nasdaq
Mainz Biomed (MYNZ) Stock Soars In Pre-Hour Session On A New Partnership - Stocks Telegraph
Mainz Biomed stock higher on Quest deal (MYNZ:NASDAQ) - Seeking Alpha
Mainz Biomed partners with Quest for colorectal cancer test - Investing.com
Mainz Biomed Forms Agreement with Quest Diagnostics to - GlobeNewswire
Mainz Biomed Partners with Quest Diagnostics for Major Colorectal Cancer Screening Study - StockTitan
Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline - Investing.com
Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline By Investing.com - Investing.com South Africa
Mainz Biomed Secures $8 Million in Follow-On Offering - TipRanks
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering - GlobeNewswire
Mainz Biomed Secures $8M Through Strategic Follow-on Offering with Dual-Warrant Structure - StockTitan
Mainz Biomed prices $8M offering of shares and warrants - MSN
Mainz Biomed Prices $8 Million Follow-On Offering to Boost Diagnostics Operations - TipRanks
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules - The Manila Times
Mainz Biomed Announces $8M Follow-On Offering with Dual Warrant Structure - StockTitan
Mainz Biomed Partners With Thermo Fisher To Advance Colorectal Cancer Screening - Contract Pharma
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific - Benzinga
Mainz Biomed stock hits 52-week low at $0.18 amid market challenges - Investing.com India
Mainz Biomed announces 1-for-40 reverse stock split - Medical Buyer
Mainz Biomed (NASDAQ:MYNZ) Shares Set to Reverse Split on Tuesday, December 3rd - Defense World
Mainz Biomed Announces Stock Split - GlobeNewswire
Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues | MYNZ Stock News - StockTitan
Q3 EPS Estimates for Mainz Biomed Increased by HC Wainwright - Defense World
Mainz Biomed (NASDAQ:MYNZ) Rating Lowered to “Neutral” at HC Wainwright - Defense World
What You Didn’t Know About Mainz Biomed N.V (NASDAQ: MYNZ) This Week - Stocks Register
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test - Nasdaq
Mainz Biomed and Thermo Fisher Scientific sign a collaboration agreement - Wiley
Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance - TipRanks
MAINZ BIOMED NV- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - Citybuzz
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening - Nasdaq
Mainz Biomed N.V. and Thermo Fisher Scientific Inc. Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - Marketscreener.com
Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire
Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough | MYNZ Stock News - StockTitan
Mainz Biomed Partners with Thermo Fisher to Advance Colorectal Cancer Screening - Contract Pharma
Is Now The Time To Buy Mainz Biomed N.V. (NASDAQ: MYNZ) Stock? - Stocks Register
Mainz Biomed’s half-yearly revenue increases 4% YoY - Medical Buyer
Mainz Biomed restructured operations, implemented cost reductions - Yahoo Finance
Mainz Biomed reports revenue growth and reduced losses By Investing.com - Investing.com South Africa
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed Highlights Growth and Innovations for 2025 - TipRanks
Mainz Biomed N : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Form 6 K - Marketscreener.com
Financial Metrics Unveiled: Mainz Biomed N.V. (MYNZ)’s Key Ratios in the Spotlight - The Dwinnex
Mainz Biomed N.V.: Navigating Market Fluctuations with a 5.69M Market Cap - The InvestChronicle
Stocks of Mainz Biomed N.V. (MYNZ) are poised to climb above their peers - SETE News
Evaluating MYNZ’s financial ratios for a profitable investment - US Post News
0.57%
2.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):